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Summary The growth inhibitory effect of tumour promoters on human leukaemia and lung cancer cell lines
was examined using the [3-(4,5 dimethylthiazol)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. The four cell
lines used were the K562 human leukaemia cell line, its adriamycin (ADM)-resistant subline (K562/ADM),
which shows the mdr phenotype, PC-9 (a human lung adenocarcinoma cell line) and its cisplatin (CDDP)-
resistant subline (PC-9/CDDP), which does not show the mdr phenotype. Phorbol 12-tetradecanoate-13-acetate
(TPA) and the TPA-type tumour promoters, aplysiatoxin and debromoaplysiatoxin, inhibited the growth of
the two parental cell lines, K562 and PC-9. The non-TPA-type tumour promoter, okadaic acid, also inhibited
the growth of the two parental cell lines in a dose-dependent manner. TPA-type and okadaic acid inhibited the
growth of K562/ADM more weakly than that of K562, and showed no growth inhibition in PC-9/CDDP.
Anhydrodebromoaplysiatoxin, an inactive derivative of the TPA-type tumour promoter, could suppress the
growth of K562 and K562/ADM only at high concentration (more than 50 pM) and it showed similar growth
inhibitory effects on the two cell lines. Okadaic acid tetramethyl ether, the inactive form of the non-TPA-type
tumour promoter did not inhibit the growth of any of the cell lines. The growth inhibitory effect of these
compounds was well correlated with their tumour-promoting activity. A study of the accumulation of okadaic
acid revealed that the amount of 3H-okadaic acid in K562/ADM and PC-9/CDDP was similar to that in their
parental cells indicating that cross-resistance to this tumour promoter in the drug-resistant cell lines is not due
to a difference in the amount of drug accumulated in sensitive and resistant cells. These results suggest the
presence of another common mechanism for resistance to ADM and CDDP as well as to TPA- or non-TPA-
type tumour promoters.
Phorbol esters such as TPA have several biological activities.
TPA activates protein kinase C (PKC) which has been con-
sidered to be a key enzyme involved in promotion, cell
differentiation and proliferation. On the other hand, there are
several reports that activation of protein kinase C by phorbol
ester modulates resistance to anticancer drugs such as vincris-
tine and etoposide in breast cancer or small cell carcinoma
cell lines (Ferguson & Cheng, 1987). Modulation of drug
resistance by TPA is possibly due to phosphorylation of
P-glycoprotein, although the modulatory effects are transient
(Hamada et al., 1987). To investigate this, we examined the
sensitizing effects of TPA to anticancer drugs using the
K562/ADM cell line which possesses the mdr phenotype and
its parental cell line K562. Modulatory effects of TPA were
not however observed in this assay system (unpublished
data). However, in the course of these studies, we observed
that TPA showed a growth inhibitory effect on K562 and
K562/ADM cells but did not induce differentiation in these
cells. Because of this result, we considered that these cells
may be useful to study the growth inhibitory effects of
tumour promoters in the absence of cell differentiation. We
also found TPA to have different inhibitory effects on the
growth of parental and drug-resistant cell lines. K562/ADM
and PC-9/CDDP revealed cross-resistance to TPA. These
data suggested that tumour promoters may be useful com-
pounds in the elucidation of new mechanisms of drug resis-
tance.
On the other hand, recent reports suggest that some com-
pounds such as bryostatin II, which have activity resembing
that of phorbol ester, show cytotoxic effects towards some
tumour cells. The mechanisms of antitumour activity of these
compounds are considered to be activation of a specific
isozyme of PKC, or down regulation of PKC. We considered
that the elucidation of the relationship between the growth
inhibitory effects and the tumour promoting activity of
tumour promoters would be useful not only for the develop-
ment of new anticancer drugs, but also for the elucidation of
unknown mechanisms of resistance to drugs. We have,
therefore, examined the growth inhibitory effect of several
tumour promoters on drug sensitive and resistant cell lines.
Materials and methods
Cell lines The human leukaemia cell line, K562, and the
human lung cancer cell line, PC-9 together with their drug-
resistant sublines were used for the study. K562 was estab-
lished from a patient with chronic myelocytic leukaemia. Its
adriamycin-resistant subline, K562/ADM, was kindly
donated by Professor T. Tsuruo, Tokyo University. PC-9,
derived from a previously untreated patient with adenocar-
cinoma of the lung, was provided by Professor Y. Hayata,
Tokyo Medical College. Its cisplatin-resistant subline, PC-9/
CDDP was established by continuous exposure to a stepwise-
increasing concentration of cisplatin (to 0.1 jg ml-') and
selection by limiting dilution technique. This cell line showed
4.2-fold resistance to cisplatin compared to the respective
parental cell line, PC-9, based on the 50% inhibitory concen-
trations (ICm) in a tetrazolium dye (MTT) assay with con-
tinuous drug exposure (Hong et al., 1988). All cell lines grew
in RPMI 1640 medium (Gibco Laboratories, Tokyo Japan)
supplemented with 10% fetal bovine serum (Gibco), penicill-
in (100 U ml-') and streptomycin (100fg ml-') (RPMI-FBS)
in a humidified 5% CO2 atmosphere at 37°C. All cell lines
grew mainly as floating aggregates, although PC-9 was also
partially attached to the surface of the culture flask. The lines
were subcultured once or twice per week.
Tumour promoters TPA and the TPA-type tumour pro-
moters, aplysiatoxin and debromoaplysiatoxin, and a non-
TPA-type tumour promoter, okadaic acid, were used in these
experiments. Anhydrodebromoaplysiatoxin and okadaic acid
tetramethyl ether were used as inactive, control compounds.
TPA was purchased from Sigma Chemical Co. St. Louis
MO. Other tumour promoters and their derivatives,
aplysiatoxin and debromoaplysiatoxin have an acetogenic,
phenolic bislactone structure (Figure 1). Okadaic acid is a
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Figure 1 Structures of tumour promoters.
toxic polyether compound of a C38 fatty acid. Structures of
the tumour promoters are shown in Figure 1. [27-3HJokadaic
acid was synthesised as reported previously (Suganuma et al.,
1989). Tumour promoters were dissolved in dimethyl sulfox-
ide (DMSO) (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) and stored at -70°C until use.
Growth inhibition assay The MTT assay used was essentially
the same as that previously reported by Mosmann (1983).
This assay is dependent on the reduction of MTT (3,4,5
dimethylthiazol-2,5 diphenyl tetrazulium bromide) mitochon-
drial dehydrogenase in viable cells to a blue formazan prod-
uct that can be measured spectrophotometrically. Single cell
suspensions were obtained by mechanical disaggregation of
the cell lines. After viability had been confirmed, the suspen-
sions were diluted with RPMI-FBS to the seeding concentra-
tions, and plated in 96-well microculture plates (Falcon
3072). The cells were plated 103 cells per well in 200gl of
medium. Anticancer agents and tumour promoters were dis-
solved in DMSO and diluted with RPMI + FBS to give a
final concentration of DMSO of 0.1%. Tumour promoters at
various concentrations were added in 20 Il culture medium,
the control culture receiving 20jil of RPMI containing 0.1%
DMSO. The plates were then incubated at 37C in a CO2
incubator. After 4 days of drug treatment, 20 il of MTT
solution (5 mgml-' in PBS, Sigma) was added into each wellCROSS-RESISTANCE TO TUMOUR PROMOTERS 417
of the culture and the plates incubated at 37°C for a further
4 h. After centrifugation of the plates at 1,500 r.p.m. for
5 min, the medium was aspirated from the wells as complete-
ly as possible without disturbing the formazan crystals and
cells on the plastic surface. A volume of 200 il of DMSO
was then added to each well and the plate was agitated on a
plate shaker for 5 min resulting in good solubilization of the
formazan crystals. The optical density (O.D.) was measured
at 560 and 690 nm using a Titertek Multiskan MCC spectro-
photometer (Flow Laboratories Japan Inc., Tokyo, Japan).
As a background, a well containing only RPMI-FBS plus
MTT containing 0.1% DMSO was used. Each experiment
was performed in triplicate. The IC,, was defined as the
concentration needed for 50% reduction of optical density in
each test and fractional absorbance was calculated as (mean
absorbance in three test wells - absorbance in a background
well)/(mean absorbance in three control wells - absorbance
in a background well) x 100. Relative resistance was defined
as IC50 for resistant subline/IC50 for parental cell line.
Intracellular uptake of [27-'H] okadaic acid K562, K562/
ADM, PC-9 or PC-9/CDDP cells (1 x 106) in 0.5 ml of
RPMI-FBS were incubated at 37°C for 30 min in a shaking
water bath, then at 37°C in the presence of various concen-
trations of ['H]okadaic acid solution. The specific activity of
labelled okadaic acid was 14 Ci nM'. At 2 h intervals, the
suspensions were well mixed and 0.5 ml quantities were trans-
ferred to Eppendorf tubes containing 0.5 ml of a mixture of
silicon oil (HIVAC-F-4, Shin-Etsu Chemical. Co. Ltd.,
Tokyo, Japan) and paraffin oil (Wako Pure Chemical Co.
Ltd., Osaka, Japan) (50:15), and centrifuged at 15,000 r.p.m.
for 3 min. After removal of the supernatant the pelleted cells
were lysed overnight with 1 ml of 1% sodium dodecyl sulfate
(SDS) (Bio-Rad Laboratories, Richmond, Calif., USA) and
transferred to scintillation vials and 10 ml of scintillator
cocktail (ACS II, Amersham Japan Ltd., Tokyo, Japan) was
added. The radioactivity was counted in a Beckham LS 3801
liquid scintillation counter (Beckman Instruments, Inc.,
Fullerton, Calif., USA). The experiment was repeated in
order to confirm the reproducibility.
Assay of tumour promoting activity Carcinogenesis was
initiated by a single application of 100 jig of DMBA dis-
solved in 0.1 ml of acetone to the skin of the backs of
8-week-old female CD-1 mice as reported previously (Fujiki
et al., 1989a). Starting one week after initiation, 2.5 fig of a
tumour promoter, dissolved in 0.1 ml of acetone, was applied
to the same area on the mice, twice weekly. Control groups
were treated with DMBA alone. Each group consisted of 15
mice. Tumour promoting activity was evaluated macro-
scopically in terms of percentage of tumour-bearing mice and
average number of tumours per mouse. Histological evalua-
tion was not performed in this experiment. The percentages
of tumour-bearing mice and average number of tumours per
mouse were recorded 30 weeks after the beginning of tumour
promotion as reported previously (Fujiki 1989b).
Results
Drug resistance of cell lines The adriamycin-resistant cell
line K562/ADM, was 8.4 times more resistant to adriamycin
than K562 but did not show cross-resistance to cisplatin. On
the other hand, the cisplatin resistant line PC-9/CDDP was
4.2-fold resistant to cisplatin compared with PC-9, but
showed no cross-resistance to adriamycin. This is consistent
with the evidence that the mdr-l gene is not involved in
cisplatin resistance. Doubling times of K562 and K562/ADM
were 16.8 h and 12.0 h, respectively, while doubling times of
PC-9 and PC-9/CDDP were 62.4 h and 52.8 h respectively.
(Table I).
Growth inhibitory effects of tumour promoters The growth
inhibitory effects of TPA and okadaic acid, as well as their
derivatives without tumour-promoting activity in these cell
lines, were determined by MTT assay. The growth of these
cell lines was inhibited by TPA and okadaic acid in a dose-
dependent manner. However, K562/ADM was relatively
resistant to both tumour promoters and the cross-resistance
indices were 15.0 and 3.6 for TPA and okadaic acid, respec-
tively. On the other hand, both cell lines were quite resistant
to the inactive derivatives, anhydrodebromoaplysiatoxin and
okadaic acid tetramethyl ether. There was no difference in
the growth inhibitory effects of these compounds on K562
and K562/ADM cells. PC-9 cells were relatively resistant to
TPA and okadaic acid compared with K562, and PC-9/
CDDP cells were completely resistant to all the compounds
(Table II).
The growth inhibitory activities of the other two TPA-type
tumour promoters such as aplysiatoxin and debromoap-
lysiatoxin with moderate tumour promoting activity were
tested against the four cell lines (Table II). Both compounds
showed lower growth inhibitory effect on K562, K562/ADM
and PC-9 cells than those produced by TPA. From these
results, there seems to be some correlation between the
growth inhibitory and tumour promoting activity of the
tumour promoters.
Correlation between tumour promoting activity and growth
inhibiton by tumour promoter in K562 and K562/ADM The
correlation between tumour promoting activity and growth
Table I Characteristics of resistant cell lines
ADMA CDDPb Doubling time
Cell line IC50' (nMml-') IC50' (nMml-') (h)
K562 13.3 16.8
K562/ADM 112.1 (8.4d) 12.0
PC-9 11.5 62.4
PC-9/CDDP 48.0 (4.2)d 52.8
aADM: adriamycin, bCDDP:cisplatin,cIC": thedrugconcentration
reducing thefractional absorbanceintheMTTassay to 50%,d Relative
resistance value: IC" of resistant cell lines/ IC50 of parent cell lines.
Table II Growth inhibitory effect and tumour promoting activity of tumour promoters
IC5ga (pM) Tumourpromoting activity
Tumour promoter K562 K562/ADM PC-9 PC-9/CDDP (Number oftumoursl
mouse in 30 weeks)
TPAb 0.3 4.5 (15.0)' 15.6 > 1620 (> 104) 11.0
Aplysiatoxin 19.3 24.1 (1.7) 19.8 >760 (> 38.5) 3.4
Debromoaplysiatoxin >3460 >3460 1505 >8650 (>5.7) 2.9
Anhydrodebromo- 69.6 69.6 (1.0) > 5220 > 5220 0.4
aplysiatoxin
Okadaic acid 2.2 7.9 (3.6) 24.0 >372 (> 19.4) 4.6
Okadaic acid >25200 >25200 >25200 >25200 0.0
tetramethyl ether
a IC5,: the drug concentration inhibiting the growth of tumour cells by 50%; b TPA: Phorbol
12-tetradecanoate-13-acetate; c Relative resistance value: IC,0 of resistant cell line/IC50 ofparent cell line.418 K. NISHIO et al.
inhibition by these compounds was further examined in K562
and K562/ADM cells (Figure 2). The tumour-promoting
activity was expressed as the average numbers of tumours per
mouse at 30 weeks of tumour promotion as described in
'Material and methods' and was found to be well correlated
with the IC50s in K562 and K562/ADM cells. The correlation
coefficients between these two parameters were r = 0.915 and
0.822. There was a similar trend in PC-9/CDDP cells. How-
ever, it was impossible to calculate the correlation coefficient
because the IC5o value in PC-9/CDDP could not be obtained
for the majority of compounds.
Accumulation of 3H-okadaic acid In order to answer the
question of whether the sensitivity to a tumour promoter is
associated with a difference in drug accumulation, a study of
[3H]okadaic acid accumulation was carried out in these four
cell lines. Labelled TPA and other TPA-type tumour pro-
moters were not used in this experiment, because the
majority of TPA-type tumour promoters bind to membrane
located receptors for phorbol ester and thus are not suitable
for such a direct accumulation study. There were no
differences in the accumulation of 3H-okadaic acid between
K562 and K562/ADM (Figure 3, Table III) or between PC-9
and PC-9/CDDP (Table III). The efflux of 3H-okadaic acid
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Figure 3 Kinetics of intracellular net uptake and efflux of 3H-
okadaic acid in K562 (0) and K562 ADM (0).
Table III Accumulation of 3H-okadaic acid
Intracellular 3H-okadaic acid (dpm/2 x 106 cells)
3H-OA (nM) K562 K562/ADM PC-9 PC-9/CDDP
2a 569.2 408.2 358.0 290.8
10 1089.5 2775.2 2049.0 1739.8
50 4718.2 5080.2 7334.2 9575.7
a Concentration of3H-okadaic acid.
was also evaluated in K562 and K562/ADM. There was no
difference in the efflux of 3H-okadaic acid between these cell
types. The slow efflux of 3H-okadaic acid in both cells
suggests that okadaic acid may bind with an intracellular
substrate (Figure 3). These results suggest that the cross-
resistance to tumour promoters in drug-resistant cells is not
caused by changes in drug uptake and efflux.
Discussion
Inherent and acquired resistance have been considered to be
the main cause of failure in cancer chemotherapy. Several
factors have been demonstrated to be involved in such resis-
tance. Two resistant cell lines K562/ADM and PC-9/CDDP,
were used in this study. K562/ADM has a typical (multidrug-
resistance) phenotype and its main mechanism of resistance
to adriamcyin is thought to be the increased efflux of the
anticancer drug caused by overexpression of P-170 glyco-
protein coded by the mdr-l gene (Tsuruo et al., 1986; Fojo et
al., 1985; Katner et al., 1983; Ueda et al., 1986). We
confirmed the overexpression of the mdr-l gene in K562/
ADM (Minato et al., 1990) and we demonstrated that efflux
of adriamcyin was more than 2-fold greater in K562/ADM
than in K562. Although K562/ADM was only 8.4-fold resis-
tant to adriamycin by the MTT assay, it showed about
130-fold resistance in a growth inhibition assay. (Horichi et
al., 1990). These results are consistent with the characteristics
of K562/ADM reported by Tsuruo et al. (1986). On the
other hand cisplatin resistance has usually been considered to
be multifactorial. We have recently demonstrated that an
increase of glutathione (Fujiwara et al., 1990) and a decrease
in the formation of DNA interstrand crosslinking due to a
decreased uptake of cisplatin (Bungo et al., 1990) are both
involved in cisplatin resistance. It has however been demon-
strated that expression of the mdr-1 gene is not related to
cisplatin resistance (Nakagawa et al., 1988).
In the present study, K562/ADM and PC-9/CDDP cells
showed cross resistance to TPA-type and non-TPA-type
tumour promoters. The inactive derivatives did not, however,
produce any effects on the growth of parental and resistant
cells except for the high concentration of anhydrode-
bromoaplysiatoxin in K562 and K562/ADM. We have also
demonstrated that growth inhibition by tumour promoters
correlates well with their tumour-promoting activity. This
result suggests the possibility of a common mechanism for
tumour-promoting activity and growth inhibition by tumour
promoters. The same phenomenon was observed for both
TPA- and non-TPA-type tumour promoters. We therefore
consider that TPA- and non-TPA-type tumour promoters
may be useful in the elucidation of the common mechanisms
of anticancer drug resistance. TPA-type tumour promoters,
such as TPA, aplysiatoxin, and debromoaplysiatoxin, acti-
vate protein kinase C (PKC) by binding to its phorbol ester
binding site (Fine et al., 1988). Unlike TPA and aplysiatoxin,
okadaic acid does not inhibit the specific binding of 3H-TPA
to PKC, and does not activate PKC in vitro (Fujiki &
Sugimura, 1987). This is why okadaic acid is classified as a
non-TPA-type tumour promoter. PKC is believed to be
related to drug resistance because: of the association of a
20-kD phosphoprotein with the mdr phenotype in human
breast and small cell lung cancer cell lines (Fine et al., 1985,
1986); of reversibility of the mdr phenotype by calmodulin
antagonists which also inhibit protein kinases (Tsuruo et al.,
1983); ofhigh baseline PKC activity in an adriamycin-resistant
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subline of a human nasopharyngeal carcinoma cell line com-
pared with the parental cell line (Cowan et al., 1982); and
increased vincristine efflux and resistance by the activation of
PKC in drug-sensitive MCF-7 cells (Fine et al., 1986).
Indeed, the baseline PKC activity in K562/ADM cells is
about 2-fold higher than that in K562 (unpublished data),
and a phosphoprotein of about 20 kDa is observed only in
K562/ADM cells labelled with 32P-ATP (unpublished data).
These findings suggest that decreased drug accumulation in
K562/ADM may be associated with a change in phos-
phorylation of P-glycoprotein and/or 20 kDa phosphoprotein
which is reversible by TPA-type tumour promoters. How-
ever, it is questionable whether a similar phenomenon occurs
in PC-9/CDDP because increased drug efflux is not involved
in the resistance of this line. K562/ADM and PC-9/CDDP
also showed cross-resistance to okadaic acid which does not
activate PKC. There was no difference in the accumulation of
3H-okadaic acid in the sensitive and the resistant cell lines.
These results therefore suggest that the cross-resistance to
okadaic acid in drug-resistant cells is not caused by changes
in drug uptake and efflux. Recently, it has been demonstrated
that okadaic acid can act on cells through inhibition of
protein phosphatases which induced 'apparent' activation of
protein kinases (Sassa et al., 1989). Therefore, we consider
that 'apparent' phosphorylation of cellular proteins might
influence the drug sensitivity of cells. This is the first report
demonstrating that adriamycin and cisplatin resistant cell
lines each show cross-resistance to TPA- and non-TPA-type
tumour promoters.
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